Comparing Auxilium Pharmaceuticals (AUXL) & Baxalta (BXLT)

Auxilium Pharmaceuticals (NASDAQ: AUXL) and Baxalta (NYSE:BXLT) are both biopharmaceuticals companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, risk, institutional ownership and valuation.

Earnings & Valuation

How to Become a New Pot Stock Millionaire

This table compares Auxilium Pharmaceuticals and Baxalta’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Auxilium Pharmaceuticals N/A N/A N/A ($3.27) -11.15
Baxalta N/A N/A N/A $1.19 38.67

Auxilium Pharmaceuticals is trading at a lower price-to-earnings ratio than Baxalta, indicating that it is currently the more affordable of the two stocks.

Dividends

Baxalta pays an annual dividend of $0.28 per share and has a dividend yield of 0.6%. Auxilium Pharmaceuticals does not pay a dividend. Baxalta pays out 23.5% of its earnings in the form of a dividend. Auxilium Pharmaceuticals has increased its dividend for 2 consecutive years.

Profitability

This table compares Auxilium Pharmaceuticals and Baxalta’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Auxilium Pharmaceuticals -29.78% -76.75% -11.59%
Baxalta 9.37% 14.28% 4.62%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Auxilium Pharmaceuticals and Baxalta, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Auxilium Pharmaceuticals 0 0 0 0 N/A
Baxalta 0 0 0 0 N/A

Summary

Baxalta beats Auxilium Pharmaceuticals on 6 of the 8 factors compared between the two stocks.

About Auxilium Pharmaceuticals

Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company that focuses on developing and marketing products to predominantly specialist audiences. Its core therapeutic focus continues to be in the area of urology, with an anchor position in men’s healthcare. The company’s products include Testim (testosterone gel) and testosterone gel are indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; TESTOPEL offers men an option that provides a long-acting androgenic effect; Striant (testosterone buccal system) CIII is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; STENDRA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction; among others.

About Baxalta

Baxalta Incorporated (Baxalta) is a biopharmaceutical company with a portfolio of differentiated therapies that seek to address medical needs across various disease areas, including hemophilia, immunology and oncology. Baxalta’s categories of products include Hemophilia products, such as Advate, Adynovate, Recombinate, Hemofil M, Immunate, Immunine, Rixubis and Prothromplex Total; Inhibitor Therapies products, including FEIBA and OBIZUR; Immunoglobulin Therapies products, which include GAMMAGARD LIQUID/KIOVIG, HYQVIA, GAMMAGARD S/D and SUBCUVIA; BioTherapeutics products, including FLEXBUMIN, BUMINATE, ARALAST NP, GLASSIA NP and CEPROTIN, and Oncology product, such as ONCASPAR. Baxalta Company develops, manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions, as well as oncology treatments for acute lymphoblastic leukemia.

Receive News & Ratings for Auxilium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auxilium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Blue Hills Bancorp  Announces Quarterly  Earnings Results
Blue Hills Bancorp Announces Quarterly Earnings Results
Head to Head Survey: IRIDEX  versus BioSig Technologies
Head to Head Survey: IRIDEX versus BioSig Technologies
The Children’s Place  & The Competition Head to Head Contrast
The Children’s Place & The Competition Head to Head Contrast
First Financial Co. Indiana  Announces Quarterly  Earnings Results
First Financial Co. Indiana Announces Quarterly Earnings Results
Nasdaq  Posts Quarterly  Earnings Results, Beats Expectations By $0.04 EPS
Nasdaq Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS
Blockpool  Achieves Market Cap of $4.08 Million
Blockpool Achieves Market Cap of $4.08 Million


© 2006-2018 Ticker Report. Google+.